PT-141 PT
Melanocortin agonist
Cyclic heptapeptide melanocortin agonist (bremelanotide) derived from Melanotan II, acting at MC3R and MC4R and studied in sexual-desire signalling.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Melanocortin agonist
- Category
- Reproductive & Endocrine
- Type
- Single compound
- Abbreviation
- PT
- Development and regulatory status
- US-approved prescription drug (bremelanotide, premenopausal HSDD)
What researchers study
Cyclic heptapeptide melanocortin receptor agonist (bremelanotide), derived from Melanotan II. It activates MC3R and MC4R in the central nervous system and is studied in sexual-desire and arousal signalling.
Research areas
- MC3R and MC4R signalling and sexual-function models
- Hypoactive sexual desire disorder trials
- Central melanocortin pathway pharmacology
- Melanocortin receptor agonist selectivity
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In two phase 3 RECONNECT trials (1,267 randomised premenopausal women with HSDD), bremelanotide was associated with significantly higher desire scores and lower distress than placebo
- phase 3 trial
Across 1,202 analysed patients, desire and distress measures favoured bremelanotide in all age, weight, BMI and baseline testosterone subgroups, with few exceptions
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Melanotan II (MT-2 Acetate)parent melanocortin agonist from which bremelanotide was derived
- Melanotan Irelated melanocortin agonist compared across receptor subtypes
- ACTH 1-39endogenous melanocortin agonist sharing the receptor family
